32 results on '"Leong, Jennifer"'
Search Results
2. Bilateral Knee Lyme Arthritis in Children: A Report of 3 Cases
3. Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma
4. Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
5. Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients
6. Clinical Reasoning: A 54-year-old woman with confusion and visual disturbances
7. Sa1396: ANTIVIRAL THERAPY IMPROVES SURVIVAL IN VIRAL-ASSOCIATED HEPATOCELLULAR CARCINOMA AFTER LIVER RESECTION BUT IS SEVERELY UNDERUTILIZED
8. Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR
9. Lamivudine resistance leading to de novo hepatitis B infection in recipients of hepatitis B core antibody positive liver allografts
10. Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice
11. Differential characteristics and outcomes of Asian and non‐Asian patients with HBV‐related hepatocellular carcinoma
12. 816 RACIAL AND ETHNIC DISPARITIES IN DIRECT-ACTING ANTIVIRAL (DAA) TREATMENT AND SURVIVAL OUTCOMES FOR TREATED/SVR (SUSTAINED VIROLOGIC RESPONSE) AND UNTREATED/NON-SVR PATIENTS WITH HEPATITIS C-RELATED HEPATOCELLULAR CARCINOMA (HCV-HCC): A REAL-HCC STUDY
13. Effects of Cirrhosis and Diagnosis Scenario in Metabolic‐Associated Fatty Liver Disease‐Related Hepatocellular Carcinoma
14. Jennifer Leong
15. Tuberculosis Treatment With a 3‐Drug Rifamycin‐Free Regimen in Liver Transplant Recipients
16. Abstract 3202: A probody drug conjugate targeting CD166 (ALCAM) enhances preclinical antitumor activity of a probody therapeutic targeting PD-1
17. Clinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma
18. Effects of Cirrhosis and Diagnosis Scenario in Metabolic‐Associated Fatty Liver Disease‐Related Hepatocellular Carcinoma.
19. Tuberculosis Treatment With a 3‐Drug Rifamycin‐Free Regimen in Liver Transplant Recipients.
20. 620 - Ethnic Differences in HCV-Related Hcc (HCV-HCC) Outcomes: Report from the Real-World Evidence by the Asia Pacific Rim Liver Consortium for HCC (Real-HCC)
21. Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results
22. Male Sex is a Risk Factor for Poorer Long-Term Overall Survival for White Patients with Hepatocellular Carcinoma (HCC) but not for Black Patients with HCC
23. Black Patients with Hepatocellular Carcinoma (HCC) Diagnosed After 2010 have Worse Long-Term Survival Than White Patients
24. Barring the Bard: Actor Jennifer Leong on confronting attempts to censor performances of Shakespeare around the world
25. Mo1468 A Case of Hepatitis E
26. Tu1672 Low Rates of Antiviral Therapy in Chronic Hepatitis B (CHB) Patients and Its Geographic Variation: A Systematic Review and Meta-Analysis of 13 Studies and 31,342 Patients
27. A Case of Intrahepatic Arterioportal Fistula After Liver Biopsy
28. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus
29. Hepatitis B surface antigen escape mutations: Indications for initiation of antiviral therapy revisited
30. Antiviral Therapy, Treatment Eligibility, and Treatment Rates in Patients Meeting Treatment Criteria in Chronic Hepatitis B in Diverse Practice Settings: A Systematic Review and Meta-analysis of 9 Studies and 22,768 Patients
31. Mo1421 - Male Sex is a Risk Factor for Poorer Long-Term Overall Survival for White Patients with Hepatocellular Carcinoma (HCC) but not for Black Patients with HCC
32. Mo1409 - Black Patients with Hepatocellular Carcinoma (HCC) Diagnosed After 2010 have Worse Long-Term Survival Than White Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.